These findings emphasize that Shc3 overexpression enhances ErbB2 translocation and activates the ErbB2‐COX2‐MDR1 axis, which contributes to the initiation and progression of MDR and aggressive behavior in breast cancer cells. Here, ERBB2 is linked to breast carcinoma.